446313-58-2Relevant academic research and scientific papers
Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent
Miwatashi, Seiji,Arikawa, Yasuyoshi,Kotani, Etsuo,Miyamoto, Maki,Naruo, Ken-Ichi,Kimura, Hiroyuki,Tanaka, Toshimasa,Asahi, Satoru,Ohkawa, Shigenori
, p. 5966 - 5979 (2007/10/03)
The p38 mitogen-activated protein (MAP) kinase has been implicated in the proinflammatory cytokine signal pathway, and its inhibitors are potentially useful for the treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and inflammat
MEDICINAL COMPOSITIONS
-
, (2008/06/13)
The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.
JNK INHIBITOR
-
Page/Page column 92, (2010/02/07)
The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.
